Kwan, Angela T. H.
Guo, Ziji
Ceban, Felicia
Le, Gia Han
Wong, Sabrina
Teopiz, Kayla M.
Rhee, Taeho Greg
Ho, Roger
Di Vincenzo, Joshua D.
Badulescu, Sebastian
Meshkat, Shakila
Cao, Bing
Rosenblat, Joshua D.
d’Andrea, Giacomo
Dev, Donovan A.
Phan, Lee
Subramaniapillai, Mehala
McIntyre, Roger S. http://orcid.org/0000-0003-4733-2523
Clinical trials referenced in this document:
Documents that mention this clinical trial
Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine
https://doi.org/10.1007/s12325-024-02826-9
Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis
https://doi.org/10.1007/s12325-023-02760-2
Article History
Received: 22 January 2024
Accepted: 19 February 2024
First Online: 23 March 2024
Declarations
:
: Dr. Roger S. McIntyre has received research grant support from CIHR, GACD, National Natural Science Foundation of China (NSFC), and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, and Atai Life Sciences. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Dr. Roger S. McIntyre is an editor-in-chief/editorial board member of<i> Advances in Therapy</i>. Dr. Roger S. McIntyre was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Felicia Ceban, Kayla M. Teopiz and Mehala Subramaniapillai received fees from Braxia Scientific Corp. Dr. Taeho Greg Rhee was supported in part by the National Institute on Aging (NIA) (#R21AG070666; R21AG078972), National Institute of Mental Health (#R21MH117438), National Institute on Drug Abuse (#R21DA057540) and Institute for Collaboration on Health, Intervention, and Policy (InCHIP) of the University of Connecticut. Dr. Rhee serves as a review committee member for Patient-Centered Outcomes Research Institute (PCORI) and Substance Abuse and Mental Health Services Administration (SAMHSA) and has received honoraria payments from PCORI and SAMHSA. Dr. Rhee has also served as a stakeholder/consultant for PCORI and received consulting fees from PCORI. Dr. Rhee serves as an advisory committee member for International Alliance of Mental Health Research Funders (IAMHRF). Dr. Rhee is currently a co-Editor-in-Chief of <i>Mental Health Science</i> and has received honorarium payments annually from the publisher, John Wiley & Sons, Inc. Dr. Roger Ho has received funding from the National University of Singapore iHeathtech Other Operating Expenses (A-0001415-09-00).
: A local research ethics board (REB) approved the primary study, which is currently published (NCT05047952). The study adhered to the guidelines of Good Clinical Practice (ICH, 1996) and the Declaration of Helsinki (WMA, 2008), with the trial design receiving approval from a local research ethics board (REB). The protocol and dataset presented herein are derived from the primary study, which aimed to investigate the efficacy of vortioxetine in treating cognitive deficits in individuals with PCC and is currently published (ClinicalTrials.gov number NCT05047952). All procedures involving human subjects/patients were approved by Advarra (Pro00055939).